hotspot -WSS

hotspot

author：focus 2025-09-27 19:29:11 - browse：951

Light micrograph of a fatty liver — Large vacuoles of triglyceride fat, accumulated inside liver cells. Adobe

SAN DIEGO — An experimental obesity drug from Eli Lilly significantly reduced liver fat in a small analysis, supporting further studies of the treatment against nonalcoholic fatty liver disease, an increasingly common condition that lacks approved treatments.

Among 98 patients with nonalcoholic fatty liver disease, those on the highest dose tested of the drug, retatrutide, experienced an 86% decrease in liver fat over 48 weeks, with most of the reduction occurring early on in treatment, according to data presented here at the American Diabetes Association conference Monday.

Additionally, 93% of people on the highest dose achieved resolution of fatty liver disease, defined as having 5% or less liver fat.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Fetal cell organoids grown from amniotic fluid, study finds

explore

WSS

IVG is promising — but it won’t replace IVF quite yet

Stop Congress from blocking public access to science

The United States is paying nearly triple for new Covid vaccines

Florida health officials providing scant details on measles cases

What will Novo Nordisk's VC do with its influx of cash?

6 solutions to address cancer drug shortages and others

leisure time

hotspot

hotspot

Drug repurposing or repositioning? The language matters

Medicare drug price negotiation continues, as pharma counteroffers

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Medicare drug price negotiation continues, as pharma counteroffers

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Stem cell biologist probes earliest stages of human development

After affirmative action ruling, medical educators look to 'holistic review'

Stop Congress from blocking public access to science

Wildfire smoke exposes gaps in outdoor worker protections

6 solutions to address cancer drug shortages and others

leisure time

The stability of $0 premiums in Medicare Advantage

Some top drug companies are starting to take action on climate

Why Talkspace is targeting Medicare, a tricky market

He's 19 months old and has one of the world’s rarest diseases

Why Talkspace is targeting Medicare, a tricky market

The Karikó problem: Lessons for funding basic research

leisure time

explore

entertainment

knowledge